PLX PROTALIX BIOTHERAPEUTICS INC US FDA Inspections 8-K Filing 2024 - Clinical Trial Update Protalix BioTherapeutics announced that data from its phase I clinical trial of PRX-115 for uncontrolled gout will be presented at the ACR Convergence 2024 conference in November.Get access to all SEC 8-K filings of the PROTALIX BIOTHERAPEUTICS INC